Santhera Pharmaceuticals Holding AG

Research Santhera Pharmaceuticals Holding AG (SANN) on Bullrun: market cap CHF 243.94M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CHF 243.94M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CHF 77.19M-CHF 49.24M-CHF 34.82M19.7%-3.78CHF 22.44MCHF 48.95M-CHF 11.82M
FY2024CHF 39.12M-CHF 41.97M-CHF 35.68M60.3%-3.69CHF 40.93MCHF 40.62MCHF 27.70M
FY2023CHF 103.41MCHF 54.78MCHF 23.53M96.9%5.01CHF 30.37MCHF 21.55MCHF 59.94M
FY2022CHF 7.47M-CHF 71.08M-CHF 33.80M51.9%-11.67CHF 1.35MCHF 44.44M-CHF 43.69M
FY2021-CHF 1.60M-CHF 55.53M-CHF 37.37M336.2%-16.2CHF 21.21MCHF 42.98MCHF 1.33M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14CHF 243.94Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CHF.

About Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Santhera Pharmaceuticals Holding AG's market cap?

Santhera Pharmaceuticals Holding AG's market capitalization is CHF 243.94M.

What does Santhera Pharmaceuticals Holding AG do?

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.